Rezolute, Inc. (RZLT)
Automate Your Wheel Strategy on RZLT
With Tiblio's Option Bot, you can configure your own wheel strategy including RZLT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RZLT
- Rev/Share 0.0
- Book/Share 1.423
- PB 1.6584
- Debt/Equity 0.0099
- CurrentRatio 15.1541
- ROIC -0.5551
- MktCap 218827703.0
- FreeCF/Share -0.6816
- PFCF -3.1043
- PE -3.1621
- Debt/Assets 0.0092
- DivYield 0
- ROE -0.6282
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | RZLT | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Dec. 11, 2025 |
| Downgrade | RZLT | Craig Hallum | Buy | Hold | -- | $2 | Dec. 11, 2025 |
| Downgrade | RZLT | Wedbush | Outperform | Neutral | -- | $1 | Dec. 11, 2025 |
| Initiation | RZLT | Guggenheim | -- | Buy | -- | $11 | Aug. 27, 2024 |
News
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
Published: January 08, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. - RZLT
Published: January 08, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rezolute, Inc. ("Rezolute" or the "Company") (NASDAQ: RZLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. - RZLT
Published: January 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rezolute, Inc. (“Rezolute” or the “Company”) (NASDAQ: RZLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
Published: January 06, 2026 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. ("Rezolute" or the "Company") (NASDAQ: RZLT).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. - RZLT
Published: January 01, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rezolute, Inc. ("Rezolute" or the "Company") (NASDAQ: RZLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT
Published: December 31, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Dec. 31, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. ("Rezolute" or the "Company") (NASDAQ: RZLT).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. - RZLT
Published: December 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rezolute, Inc. (“Rezolute” or the “Company”) (NASDAQ: RZLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT
Published: December 29, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses in Rezolute to Contact Him Directly to Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 29, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. ("Rezolute" or the "Company") (NASDAQ: RZLT).
Read More
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
Published: December 23, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Dec. 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. ("Rezolute" or the "Company") (NASDAQ: RZLT).
Read More
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating
Published: December 23, 2025 by: PRNewsWire
Sentiment: Neutral
RZLT Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO , Dec. 23, 2025 /PRNewswire/ -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug ("erso"). The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism ("HI").
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
Published: December 21, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)---- $RZLT #Faruqi--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. (“Rezolute” or the “Company”) (NASDAQ: RZLT). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. Rezolute, Inc. shares tumbled sharply on December 11, 202.
Read More
REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT
Published: December 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options
Read More
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating
Published: December 18, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Dec. 18, 2025 /PRNewswire/ -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug ("erso"). The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism ("HI").
Read More
RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Rezolute shares collapse 79% so far in December after a phase III hyperinsulinism study of its only pipeline candidate miss primary and key secondary endpoints.
Read More
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
Published: December 17, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Dec. 17, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. ("Rezolute" or the "Company") (NASDAQ: RZLT).
Read More
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating RZLT Investors with Losses Encouraged to Contact the Firm
Published: December 15, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Dec. 15, 2025 /PRNewswire/ -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug ("erso"). The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism ("HI").
Read More
Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Rezolute (RZLT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses
Published: December 12, 2025 by: Newsfile Corp
Sentiment: Neutral
Boston, Massachusetts--(Newsfile Corp. - December 12, 2025) - Block & Leviton is investigating Rezolute, Inc. (NASDAQ: RZLT) for potential securities law violations. Investors who have lost money in their Rezolute, Inc. investment should contact the firm to learn more about how they might recover those losses.
Read More
Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT
Published: December 11, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT.
Read More
Rezolute, Inc. (RZLT) Discusses Phase 3 sunRIZE Study Results and Challenges in Congenital Hyperinsulinism Transcript
Published: December 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Rezolute, Inc. (RZLT) Discusses Phase 3 sunRIZE Study Results and Challenges in Congenital Hyperinsulinism Transcript
Read More
INVESTOR ALERT: Investigation of Rezolute, Inc. (RZLT) by Holzer & Holzer, LLC
Published: December 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Rezolute, Inc. (“Rezolute” or the “Company”) (NASDAQ: RZLT) complied with federal securities laws. On December 11, 2025, Rezolute announced topline results from its Phase 3 sunRIZE study, which did not meet the primary endpoint or the key secondary endpoint. Following this news, the price of the Company's stock dropped.
Read More
Rezolute shares plunge on disappointing Phase 3 congenital hyperinsulinism trial results
Published: December 11, 2025 by: Proactive Investors
Sentiment: Negative
Rezolute (NASDAQ:RZLT) shares fell sharply today following the announcement that its Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism (HI) did not meet its primary endpoint. The stock fell almost 90% to trade at $1.15 late morning on Thursday.
Read More
BREAKING: Rezolute, Inc. Shares Down Over 85%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
Published: December 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Rezolute, Inc. (Nasdaq: RZLT) for potential securities law violations. Investors who have lost money in their Rezolute, Inc. investment should contact the firm to learn more about how they might recover those losses.
Read More
How Much Upside is Left in Rezolute (RZLT)? Wall Street Analysts Think 56.58%
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 56.6% upside potential for Rezolute (RZLT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
All You Need to Know About Rezolute (RZLT) Rating Upgrade to Buy
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Rezolute (RZLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Can Rezolute (RZLT) Climb 49.4% to Reach the Level Wall Street Analysts Expect?
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 49.4% upside potential for Rezolute (RZLT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Rezolute Stock: FDA Fast Track Fuels 2025 Breakout
Published: September 17, 2025 by: MarketBeat
Sentiment: Positive
Rezolute, Inc.'s NASDAQ: RZLT stock price is steadily moving higher in 2025 and is expected to continue its run because of what adds up to a rapidly improving outlook. Its lead pharmaceutical candidate, Ersodetug, was granted the FDA's Breakthrough Therapy designation, which puts it on a fast track for approval.
Read More
Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Rezolute, Inc. (NASDAQ:RZLT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Nevan Elam - Founder, CEO, Principal Financial Officer & Acting Chairman of the Board Conference Call Participants Kelly McCarthy Presentation Kelly McCarthy All right. Good afternoon, everyone.
Read More
Rezolute to Participate in Upcoming Investor Conferences
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:
Read More
Rezolute to Participate in Upcoming Investor Conferences
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:
Read More
About Rezolute, Inc. (RZLT)
- IPO Date 2013-01-14
- Website https://www.rezolutebio.com
- Industry Biotechnology
- CEO Nevan Charles Elam
- Employees 64